Journal
New England Journal of Medicine
Publication Date
12-11-2021
Volume
386
Issue
7
First Page
640
Last Page
654
Document Type
Open Access Publication
DOI
10.1056/NEJMoa2116133
Rights and Permissions
Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, Ghobadi A, Rapoport AP, McGuirk J, Pagel JM, Muñoz J, Farooq U, van Meerten T, Reagan PM, Sureda A, Flinn IW, Vandenberghe P, Song KW, Dickinson M, Minnema MC, Riedell PA, Leslie LA, Chaganti S, Yang Y, Filosto S, Shah J, Schupp M, To C, Cheng P, Gordon LI, Westin JR; All ZUMA-7 Investigators and Contributing Kite Members. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med. 2022 Feb 17;386(7):640-654. doi: 10.1056/NEJMoa2116133 Copyright © 2021 Massachusetts Medical Society. Reprinted with permission.
Recommended Citation
Locke, Frederick L; Ghobadi, Armin; and et al, "Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma." New England Journal of Medicine. 386, 7. 640 - 654. (2021).
https://digitalcommons.wustl.edu/open_access_pubs/12039
Research Summary
nejmoa2116133_protocol.pdf (6686 kB)
Protocol
nejmoa2116133_appendix.pdf (728 kB)
Supplementary Appendix
nejmoa2116133_disclosures.pdf (1724 kB)
Disclosure Forms
nejmoa2116133_data-sharing.pdf (72 kB)
Data Sharing Statement
